Journal profile · GASTROENTEROLOGY & HEPATOLOGY
Hepatic Medicine-Evidence and Research
ISSN 1179-1535 · Dove Medical Press · United Kingdom
Hepatic Medicine-Evidence and Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.5 (journal website); fully open access; APC about USD 3,230; median 103 days to acceptance (22 articles, last 24 months); acceptance rate 8% (journal website); 15 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Hepatic Medicine-Evidence and Research is published by Dove Medical Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Liver Disease Diagnosis and Treatment, Hepatitis C virus research and Liver Disease and Transplantation, together about 47.9% of its articles. Its main subfields are Hepatology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Gerond V. Lake-Bakaar, MD Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.
From the journal's Aims & Scope
Research area (LetPub): GASTROENTEROLOGY & HEPATOLOGY
Editor-in-chief Lake-Bakaar BethPublisher website
Editorial board by country: 4 in mainland China (about 17%); most named United States 15, Mainland China 4, India 2, Germany 2, Israel 1 (24 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Liver Disease Diagnosis and TreatmentMedicine23.1%
- Hepatitis C virus researchMedicine13.2%
- Liver Disease and TransplantationMedicine11.6%
- Hepatitis B Virus StudiesMedicine8.9%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4.8%
- Hepatitis Viruses Studies and EpidemiologyMedicine4.8%
- Liver physiology and pathologyMedicine4.1%
- Organ Transplantation Techniques and OutcomesMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.8Publisher website ·
- h-index
- 38OpenAlex ·
- i10-index
- 120OpenAlex ·
- 2-year mean citedness
- 1.77OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 97.73%LetPub ·
Volume
- Articles per year
- 14LetPub ·
- Downloads per year (publisher)
- 39,999Publisher website ·
Articles by year OpenAlex count · 217 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 6 | 6 | 0 |
| 2025 | 15 | 15 | 26 |
| 2024 | 10 | 10 | 29 |
| 2023 | 22 | 22 | 158 |
| 2022 | 13 | 13 | 155 |
| 2021 | 17 | 17 | 331 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
103 daysMedian, submission to acceptance · P25–P75 90 days – 136 days
- Acceptance to online
- median 10 days (22 articles)
- Submission to online
- median 120 days
- Sample
- 22 articles with submission and acceptance dates (23 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 8%Publisher website ·
- Desk decision
- 55 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,230 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Plagiarism
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Plagiarism
All submitted manuscripts are checked for plagiarism using Crossref Similarity Check (powered by iThenticate). Model summary
Please be aware that Dove Medical Press checks ALL submitted manuscripts for plagiarism. We use Crossref Similarity Check (powered by iThenticate).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-1535
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Hepatic Medicine-Evidence and Research
What CAS zone is Hepatic Medicine-Evidence and Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hepatic Medicine-Evidence and Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Gastroenterology & Hepatology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hepatic Medicine-Evidence and Research?
The journal's website gives an impact factor of 2.5 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 38.
How long does peer review take at Hepatic Medicine-Evidence and Research?
Based on the dates recorded on 22 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 103 days (interquartile range 90–136 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 8%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Hepatic Medicine-Evidence and Research based?
Of the 24 board members whose country the journal's board page names, 4 (about 17%) are in mainland China; the countries named most often are United States (15), Mainland China (4) and India (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Hepatic Medicine-Evidence and Research?
According to LetPub and DOAJ records, Hepatic Medicine-Evidence and Research is indexed in ESCI and DOAJ.
Is Hepatic Medicine-Evidence and Research open access, and what is the APC?
Hepatic Medicine-Evidence and Research is a fully open-access journal. APC about USD 3,230.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .